Neurotech Pharmaceuticals’ surgically implanted cell and gene therapy, Encelto, is now FDA approved to treat macular telangectasia type 2 (MacTel). It’s the first therapy for this rare retinal degeneration disorder.
Shares of Philadelphia-based Spark were up more than 120 percent in premarket trading on the Nasdaq following the news.
Meevo offers an all-in-one solution for managing salon and spa employees. From scheduling and time tracking to payroll and promotions, Meevo streamlines operations and supports growth.
Iconic Therapeutics is using Tissue Factor biology to create new treatment for age-related macular degeneration with retinal disease in addition to cancer.